EUVIMEDEUVIMED entdecken
Crossref

Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model

Beatrice Vahle iD, Sven Weidner iD, André Tomalka iD, Antje Schauer iD, Antje Augstein iD, Anita Männel, Peggy Barthel, Janet Friedrich, Grietje Beck iD, Siegfried Labeit iD, T Scott Bowen iD, Tobias Siebert iD und 2 weitere

Circulation: Heart Failure · 2026-08 · 19 (8)

DOI: 10.1161/circheartfailure.126.014397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation: Heart Failure, 2026-08. Verfasst von Beatrice Vahle und 13 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center Dresden, Laboratory of Molecular and Experimental Cardiology, TU Dresden, Germany (B.V., A.S., A.A., A.M., P.B., J.F., A.L., V.A.). Hauptthemen laut MEDLINE: Heart Failure, Oligopeptides, Muscle, Skeletal, Stroke Volume. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF). In the context of mitochondrial dysfunction, altered cardiolipin integrity has been reported in the myocardium of HFpEF, suggesting Elamipretide, a cardiolipin stabilizing agent, as potential therapeutic approach. The present study investigated cardiolipin dysregulation in the skeletal muscle of HFpEF rats and analyzed the effect of Elamipretide treatment. METHODS: Female zucker fatty spontaneously hypertensive heart failure F1 hybrid lean (n=10, control) and obese rats (n=24, HFpEF) were included. At 20 weeks of age, HFpEF rats were randomized into 2 groups receiving NaCl (n=12) or Elamipretide (n=12) for 12 weeks. Skeletal muscle tissue was collected for whole-muscle force, single-fiber mechanics, mitochondrial respiration, histology and molecular analyses. RESULTS: HFpEF rats exhibited reduced cardiolipin levels (−6.8%, P =0.007) and maturation (shown via tafazzin expression), contractile dysfunction, titin hyperphosphorylation, fiber atrophy and increased oxidative stress markers. Elamipretide improved whole muscle (soleus: +8.2%, P =0.041, extensor digitorum longus: +10.9%, P =0.016) and single-fiber (soleus: +173.2%, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureOligopeptidesMuscle, SkeletalStroke VolumeMitochondria, MuscleAnimalsFemaleDisease Models, AnimalRats, ZuckerCardiolipinsRatsRats, Inbred SHRConnectinMuscle Contraction

Stichwörter der Autor:innen

connectinheart failuremitochondriamusclerats

Substanzen

elamipretideOligopeptidesCardiolipinsConnectin

Autor:innen und Institutionen

  • Heart Center Dresden, Laboratory of Molecular and Experimental Cardiology, TU Dresden, Germany (B.V., A.S., A.A., A.M., P.B., J.F., A.L., V.A.).
  • Motion and Exercise Science, University of Stuttgart, Germany (S.W., A.T., T.S.).
  • Integrative Pathophysiology, Department for Anesthesiology and Intensive Operative Care, Medical Faculty Mannheim, University of Heidelberg, Germany (G.B., S.L.).
  • School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, United Kingdom (T.S.B.).
  • Stuttgart Center for Simulation Science, University of Stuttgart, Germany (T.S.).

ORCID-Profile: Beatrice Vahle, Sven Weidner, André Tomalka, Antje Schauer, Antje Augstein, Grietje Beck, Siegfried Labeit, T Scott Bowen, Tobias Siebert, Axel Linke, Volker Adams

Zitieren

APA

Vahle, B., Weidner, S., Tomalka, A., Schauer, A., Augstein, A., Männel, A., Barthel, P., Friedrich, J., Beck, G., Labeit, S., Bowen, T. S., Siebert, T., Linke, A., & Adams, V. (2026). Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model. Circulation: Heart Failure, 19(8). https://doi.org/10.1161/circheartfailure.126.014397

Vancouver

Vahle B, Weidner S, Tomalka A, Schauer A, Augstein A, Männel A, et al. Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model. Circulation: Heart Failure. 2026;19(8). doi:10.1161/circheartfailure.126.014397

BibTeX
@article{Vahle2026,
  author = {Vahle, Beatrice and Weidner, Sven and Tomalka, André and Schauer, Antje and Augstein, Antje and Männel, Anita and Barthel, Peggy and Friedrich, Janet and Beck, Grietje and Labeit, Siegfried and Bowen, T Scott and Siebert, Tobias and Linke, Axel and Adams, Volker},
  title = {Targeting Mitochondrial Dysfunction With Elamipretide (SS-31) Improves Skeletal Muscle Performance in a HFpEF Rat Model},
  journal = {Circulation: Heart Failure},
  year = {2026},
  volume = {19},
  number = {8},
  doi = {10.1161/circheartfailure.126.014397}
}
Kostenlos starten →